MARKETRESEARCH
Uploaded on Nov 21, 2024
Category
Health & Medicine
According to the latest research report by IMARC Group, The global dry eye syndrome market size reached USD 5.0 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 8.0 Billion by 2033, exhibiting a growth rate (CAGR) of 4.78% during 2025-2033. More Info:- https://www.imarcgroup.com/dry-eye-syndrome-market
Category
Health & Medicine
Dry Eye Syndrome Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opportunity 2025-33
Global Dry Eye
Syndrome Market
Research and Forecast
Report 2025-2033
Format: PDF+EXCEL
© 2023 IMARC All Rights Reserved
About IMARC Group
IMARC Group is a g lobal management consul t ing f i rm that he lps the wor ld ’s most ambi t ious
changemakers to create a las t ing impact . Across the s ix major cont inents and 100+ count r ies , we
work a longside our bus iness par tners as one team wi th a common ambi t ion to achieve unparal le led
resul ts , gain a compet i t ive edge, and t ransform indust r ies . IMARC Group excels in unders tanding
i ts c l ients ’ bus iness pr ior i t ies and del iver ing ta i lored solut ions that dr ive meaningfu l outcomes. Our
c l ient base spans over 3,000 organizat ions in the pr ivate, publ ic , and soc ia l sectors , ranging f rom
high-growth s tar tups to For tune 500 companies.
We prov ide a comprehensive sui te of market entry and expansion serv ices. Our of fer ings inc lude
thorough market assessment , feas ib i l i ty s tudies, company incorporat ion ass is tance, fac tory setup
suppor t , regulatory approvals and l icens ing navigat ion, branding, market ing and sales st rategies,
compet i t ive landscape and benchmark ing analyses, pr ic ing and cost research, and procurement
research. These serv ices are des igned to ass is t companies in evaluat ing market oppor tuni t ies ,
set t ing up new ent i t ies , navigat ing regulatory landscapes, boost ing brand v is ib i l i ty , analyz ing
compet i tors, and opt imiz ing procurement s t rategies.
Acco r d ing t o t he l a t e s t r epo r t by I M ARC G r oup , t i t l ed " Dr y E ye Synd rom e M arke t :
G l o ba l I ndu st ry T re nds , Sh are , S i ze , G row t h , O pp or t u n i t y an d Fo recas t 20 25 -
2033 , " t he g loba l d r y eye synd r om e m a r ke t s i ze r eac hed U SD 5 . 0 B i l l i o n i n 2024 .
Dr y Eye Synd r om e i s a com m on eye co nd i t i on cha r ac t e r i zed by i n ad equ a t e
Report l ub r i c a t i on and m o is t u r e on t he su r f ace o f t h e ey e . I t oc cu r s when t he t ea r g lan ds f a i l t o p r odu ce en ough t e a r s o r whe n t he t ea r s ev apo r a t e t oo qu i ck l y , r esu l t i ng i n
d r yn ess , i r r i t a t i o n , and d i s com f o r t . I t i n c lude s s ym p t om s su ch as a g r i t t y o r san dy
Highlight and sen sa t i on i n t h e eye s , r edn ess , s t i ng in g o r bu r n ing sen sa t i on s , exc ess i ve t ea r i ng ,
b lu r r ed v is i on , and s ens i t i v i t y t o l i g h t .
The r e a r e se ve r a l un de r l y i ng cau ses o f d r y eye sy nd r om e , i nc lu d ing ag in g , ho r m ona l
Description cha ng es , c e r t a in m ed ica t i o ns , m ed ica l cond i t i ons su ch as au t o im m une d i s o r de r s ,
env i r onm e n t a l f ac t o r s , and l i f e s t y le cho i c es . S om e c om m on l y used t r ea t m en t s
i nc lud e t he use o f a r t i f i c i a l t e a r s o r l u b r i ca t i ng eye d r ops t o p r ov ide t em por a r y
r e l i e f .
Reque st f o r a P DF s ampl e o f t h i s repor t :
h t t p s : / / www. im ar c g r ou p . com / d r y - eye - synd r om e - m ar ke t / r equ es t s am p le
Report Description
G lo b a l D r y E y e S y n d r o m e M a r k e t T r e n d s :
L i f e s t y l e c h a n g e s a n d i n c r e a s e d s c r e e n t i m e i s d r i v i n g t h e g l o b a l m a r k e t . M o r e o v e r , w i t h t h e w i d e s p r e a d u s e o f d i g i t a l d e v i c e s
s u c h a s s m a r t p h o n e s , t a b l e t s , a n d c o m p u t e r s , i n d i v i d u a l s a r e e x p o s e d t o p r o l o n g e d p e r i o d s o f s c r e e n v i e w i n g , l e a d i n g t o
d e c r e a s e d b l i n k r a te s a n d i n c r e a s e d e v a p o r a t i o n o f t e a r s . T h i s p r o l o n g e d v i s u a l t a s k i n g a n d r e d u c e d b l i n k i n g c o n t r i b u te t o t h e
d e v e l o p m e n t o f d r y e y e s y m p t o m s , t h e r e b y f u e l i n g t h e d e m a n d f o r D E S t r e a tm e n ts . B e s i d e s , w i t h t h e g l o b a l p o p u l a t i o n a g i n g , t h e
p r e v a l e n c e o f D E S i s e x p e c t e d t o i n c r e a s e , l e a d i n g t o a g r e a t e r d e m a n d f o r e f f e c t i v e t r e a t me n t s a n d m a n a g e m e n t o p t i o n s .
F u r t h e r m o r e , v a r i o u s e n v i r o n m e n t a l f a c to r s , s u c h a s p o l l u t i o n a n d d r y c l i m a t e s , a r e a u g m e n t i n g t h e D E S m a r k e t a s e x p o s u r e t o
e n v i r o n m e n t a l p o l l u t a n t s , a l l e r g e n s , a n d i r r i t a n t s c a n t r i g g e r o r e x a c e r b a t e d r y e y e s y m p to m s , t h u s c a t a l y z i n g t h e m a r k e t .
A d d i t i o n a l l y , l i v i n g i n r e g i o n s w i t h d r y c l i m a te s o r s p e n d i n g t i m e i n a i r - c o n d i t i o n e d o r h e a te d e n v i r o n m e n ts c a n l e a d t o i n c r e a s e d
e v a p o r a t i o n o f t e a r s a n d w o r s e n e d D E S s y m p t o m s . A l o n g w i t h t h i s , c o n t i n u a l a d v a n c e m e n ts i n d i a g n o s t i c t e c h n o l o g i e s a n d
t e c h n i q u e s h a v e i m p r o v e d t h e a c c u r a c y a n d e f f i c i e n c y o f D E S d i a g n o s i s , a l l o w i n g f o r e a r l i e r d e t e c t i o n a n d i n t e r v e n t i o n . T h i s i s
c r e a t i n g a p o s i t i v e ma r k e t o u t l o o k .
L o o k in g f o r w a r d , t h e m a r k e t v a l u e i s p r o j e c t e d t o r e a c h U S D 8 . 0 B i l l i o n b y 2 0 3 3 , e x p a n d i n g a t a C A G R o f 4 . 7 8 % d u r i n g
2 0 2 5 - 2 0 3 3 .
V ie w R e p o r t T O C , F i g u r e s a n d T a b l e s : h t t p s : / / w w w . i m a r c g r o u p . c o m / d r y - e y e - s y n d r o m e - m a r k e t
Breakup by Disease Type:
• Evaporative Dry Eye Syndrome
• Aqueous Dry Eye Syndrome
Breakup by Drug Type:
• Anti- infl ammatory Drugs
• Lubricant Eye Drops
Report
• Autologous Serum Eye Drops
Segmentation
Breakup by Product:
• Liquid Drops
• Gel
• Liquid Wipes
• Eye Ointment
• Others
Breakup by Distribution Channel:
• Hospital Pharmacies
• Retai l Pharmacies
• Online Pharmacies
Breakup by Region:
Report • North America
Segmentation • Europe
• Asia Pacifi c
• Middle East and Afr ica
• Latin America
• Akorn Operating Company LLC
• Alimera Science
• Allergan plc.
• Auven Therapeutics
Competitive
• Bausch + Lomb Incorporated
Landscape • GlaxoSmithKl ine plc
with Key • Nicox S.A.
• Novart is AG
Players
• Otsuka Holdings Co., Ltd.
• Santen Pharmaceutical Co., Ltd.
What was the size of the global dry eye syndrome
market in 2024?
What is the expected growth rate of the global dry
eye syndrome market during 2025-2033?
Key
Questions What are the key factors driving the global dry eye syndrome market?
Answered in
What has been the impact of COVID-19 on the
the Report global dry eye syndrome market?
What is the breakup of the global dry eye
syndrome market based on the disease type?
What is the breakup of the global dry eye
syndrome market based on the drug type?
What is the breakup of the global dry eye
syndrome market based on the product?
What is the breakup of the global dry eye
syndrome market based on the distribution
channel?
Key
Questions What are the key regions in the global dry eye syndrome market?
Answered in
Who are the key companies/players in the global
the Report dry eye syndrome market?
1 P r e f a c e
2 S c o p e a n d M e t h o d o l o g y
2 . 1 O b j e c t i v e s o f t h e S t u d y
2 . 2 S t a k e h o l d e r s
2 . 3 D a t a S o u r c e s
2 . 3 . 1 P r i m a r y S o u r c e s
2 . 3 . 2 S e c o n d a r y S o u r c e s
2 . 4 M a r k e t E s t i m a t i o n
2 . 4 . 1 B o t t o m - U p A p p r o a c h
Table of 2 . 4 . 2 T o p - D o w n A p p r o a c h 2 . 5 F o r e c a s t i n g M e t h o d o l o g y
3 E x e c u t i v e S u m m a r y
4 I n t r o d u c t i o n
4 . 1 O v e r v i e w
Contents 4 . 2 K e y I n d u s t r y T r e n d s5 G l o b a l D r y E y e S y n d r o m e M a r k e t 5 . 1 M a r k e t O v e r v i e w
5 . 2 M a r k e t P e r f o r m a n c e
5 . 3 I m p a c t o f C O V I D - 1 9
5 . 4 M a r k e t B r e a k u p b y D i s e a s e T y p e
5 . 5 M a r k e t B r e a k u p b y D r u g T y p e
5 . 6 M a r k e t B r e a k u p b y P r o d u c t
5 . 7 M a r k e t B r e a k u p b y D i s t r i b u t i o n C h a n n e l s
5 . 8 M a r k e t B r e a k u p b y R e g i o n
5 . 9 M a r k e t F o r e c a s t
6 M a r k e t B r e a k u p b y D i s e a s e T y p e
6 . 1 E v a p o r a t i v e D r y E y e S y n d r o m e
6 . 1 . 1 M a r k e t T r e n d s
6 . 1 . 2 M a r k e t F o r e c a s t
6 . 2 A q u e o u s D r y E y e S y n d r o m e
6 . 2 . 1 M a r k e t T r e n d s
6 . 2 . 2 M a r k e t F o r e c a s t
7 M a r k e t B r e a k u p b y D r u g T y p e
7 . 1 A n t i - i n f l a m m a t o r y D r u g s
7 . 1 . 1 M a r k e t T r e n d s
7 . 1 . 2 M a r k e t F o r e c a s t
7 . 2 L u b r i c a n t E y e D r o p s
7 . 2 . 1 M a r k e t T r e n d s
7 . 2 . 2 M a r k e t F o r e c a s t
7 . 3 A u t o l o g o u s S e r u m E y e D r o p s
7 . 3 . 1 M a r k e t T r e n d s
7 . 3 . 2 M a r k e t F o r e c a s t
8 M a r k e t B r e a k u p b y P r o d u c t
8 . 1 L i q u i d D r o p s
Table of 8 . 1 . 1 M a r k e t T r e n d s
8 . 1 . 2 M a r k e t F o r e c a s t
8 . 2 G e l
Contents 8 . 2 . 1 M a r k e t T r e n d s 8 . 2 . 2 M a r k e t F o r e c a s t
8 . 3 L i q u i d W i p e s
8 . 3 . 1 M a r k e t T r e n d s
8 . 3 . 2 M a r k e t F o r e c a s t
8 . 4 E y e O i n t m e n t
8 . 4 . 1 M a r k e t T r e n d s
8 . 4 . 2 M a r k e t F o r e c a s t
8 . 5 O t h e r s
8 . 5 . 1 M a r k e t T r e n d s
8 . 5 . 2 M a r k e t F o r e c a s t
9 M a r k e t B r e a k u p b y D i s t r i b u t i o n C h a n n e l
9 . 1 H o s p i t a l P h a r m a c i e s
9 . 1 . 1 M a r k e t T r e n d s
9 . 1 . 2 M a r k e t F o r e c a s t
F o r m o r e i n f o r m a t i o n , v i s i t :
h t t p s : / / w w w. im a rcg ro u p . co m / d r y - ey e - s y n d ro m e- m a r ke t / t o c
Partial List of Clients
Partial List of Clients
Disclaimer
© 2024 IMARC Al l R ights Reserved
Th is Pub l i ca t ion and a l l i t ’ s con ten ts un less o therw ise men t i oned a re copy r i gh ted in the name o f
I n t e rna t i ona l Marke t Ana lys i s Research and Consu l t ing ( IMARC) . No pa r t o f t h i s pub l i ca t ion may be
rep roduced , repackaged , red i s t r i bu ted o r res o ld i n who le o r i n any pa r t . The pub l i ca t ion may a l so
no t be used i n any f o rm o r by and means g raph i c e lec t ron ic o r mechan ic a l , i nc lud ing pho tocopy ing ,
reco rd ing , t ap ing o r by i n fo rmat i on s to rage o r re t r ieva l , o r by any o the r f o rm, w i t hou t the exp ress
c ons en t o f I n t e rna t iona l Marke t Ana lys i s Research and Consu l t i ng ( IMARC) .
Disc la imer : Al l con ten ts and da ta o f t h i s pub l i c a t i on , i nc lud ing fo recas t s , da ta ana lys i s and op in ion
have been based on in f o rmat ion and sources be l ieved to be accu ra te and re l iab le a t t he t ime o f
pub l i sh ing . In t e rna t i ona l Ma rke t Ana l ys is Research and Consu l t ing makes no rep resen ta t ion o f
war ran t y o f any k ind as to t he acc u racy o r comp le teness o f any I n fo rmat i on p rov ided . IMARC
accep ts no l i ab i l i t y wha tsoever f o r any los s o r damage resu l t i ng f rom op in ion , e r ro rs o r
i naccu rac ies i f any f ound th is pub l i ca t ion .
IMARC, IMARC Group and G loba l Therapy I ns igh t Ser i es a re reg is t e red t rademarks o f I n te rna t iona l
Marke t Ana lys i s Research and Consu l t ing . A l l o the r t rademarks used i n th i s pub l i ca t i on a re
reg i s te red t rademarks o f t he i r r espec t i ve compan ies .
Contact Us
Visit us at :
https://www.imarcgroup.com
+1-631-791-1145
[email protected]
Stay With Us:
Comments